Cogent Biosciences (COGT) Total Non-Current Liabilities (2020 - 2026)

Cogent Biosciences' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $295.3 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 355.65% year-over-year to $295.3 million; the TTM figure through Mar 2026 stood at $295.3 million (up 355.65% YoY), while the FY2025 annual figure was $301.2 million, up 320.6% from the prior year.
• Total Non-Current Liabilities was $295.3 million for Q1 2026 at Cogent Biosciences, down from $301.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $301.2 million in Q4 2025 to a low of $43.4 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $145.0 million across 4 years, with a median of $117.4 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities surged 192.13% in 2022, then soared 355.65% in 2026.
• A 4-year view of Total Non-Current Liabilities shows it stood at $43.4 million in 2022, then jumped by 65.1% to $71.6 million in 2024, then jumped by 320.6% to $301.2 million in 2025, then fell by 1.98% to $295.3 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $295.3 million (Q1 2026), $301.2 million (Q4 2025), and $121.1 million (Q3 2025), per Business Quant data.